34. Neurofibromatosis
120 clinical trials,   182 drugs   (DrugBank: 72 drugs),   84 drug target genes,   194 drug target pathways

Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01140360
(ClinicalTrials.gov)
February 20128/6/2010Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform NeurofibromasPilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform NeurofibromasNeurofibromatosis;NeurofibromasDrug: GleevecKent RobertsonNULLCompleted3 Years65 YearsAll21Phase 1;Phase 2United States
2NCT01673009
(ClinicalTrials.gov)
May 200622/8/2012Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasPhase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasNeurofibromatosisDrug: GleevecIndiana UniversityNULLCompleted3 Years65 YearsAll36Phase 2United States